science

Nivolumab/relatlimab

Nivolumab/relatlimab is a science topic covered in the lgStudy science library. This page brings together a partial reference excerpt, illustrations, worked examples, real-world applications and a short study plan, so you can understand Nivolumab/relatlimab rather than just read about it. In short: Nivolumab/relatlimab, sold under the brand name Opdualag, is a fixed-dose combination medication use to treat melanoma. It contains nivolumab, a programmed death receptor-1 (PD-1) blocking antibody, and relatlimab, a lymphocyte activation gene-3 (LAG-3) blocking antibody.

Key takeaways

Nivolumab/relatlimab belongs to science; place it in that map before memorising details.
Learn the definition first, then one example that makes the definition concrete.
Connect Nivolumab/relatlimab to a quantity you can measure, compute or draw — that is where exam questions come from.
Reproduce the core statement of Nivolumab/relatlimab from memory before moving on to harder problems.

Reference excerpt

Nivolumab/relatlimab, sold under the brand name Opdualag, is a fixed-dose combination medication use to treat melanoma. It contains nivolumab, a programmed death receptor-1 (PD-1) blocking antibody, and relatlimab, a lymphocyte activation gene-3 (LAG-3) blocking antibody. It is given by intravenous infusion. The combination was approved for medical use in the United States in March 2022, and in the European Union in September 2022. The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.

Medical uses The combination is indicated for the first line treatment of advanced (unresectable or metastatic) melanoma in people aged twelve years of age and older. It is also currently being researched as a possible treatment for Parkinson's disease and other neurodegenerative conditions, based on early evidence that it may prevent the spread of pathologically misfolded alpha-synuclein protein (Lewy bodies) through neurons in the substantia nigra region of the brain.

Society and culture

Legal status In July 2022, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Opdualag, intended for the treatment of melanoma. The applicant for this medicinal product is Bristol-Myers Squibb Pharma EEIG. Opdualag was approved for medical use in the European Union in September 2022. In January 2024, the National Institute for Health and Care Excellence (NICE) recommended nivolumab-relatlimab as a first-line treatment of advanced melanoma in patients aged 12 years and older.

References

Further reading Tawbi HA, Schadendorf D, Lipson EJ, Ascierto PA, Matamala L, Castillo Gutiérrez E, et al. (January 2022). "Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma". N Engl J Med. 386 (1): 24–34. doi:10.1056/NEJMoa2109970. PMC 9844513. PMID 34986285. S2CID 245771473.

External links Clinical trial number NCT03470922 for "A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma (RELATIVITY-047)" at ClinicalTrials.gov

Worked examples

Example 1 — a first encounter with Nivolumab/relatlimab

Start with the simplest possible case. Write down what Nivolumab/relatlimab claims or describes in one sentence, then invent the smallest concrete situation in which that sentence is true. In science, the smallest case is usually a single object, a single equation or a single measurement. Check that every symbol or term in your sentence has a meaning in that case.

Example 2 — changing one variable

Take the situation from Example 1 and change exactly one quantity: double it, halve it, or set it to zero. Predict what should happen to Nivolumab/relatlimab before you calculate. Comparing your prediction with the result is the fastest way to find out whether you understand the idea or only the words.

Example 3 — an exam-style question

Typical questions about Nivolumab/relatlimab ask you to (a) state it precisely, (b) apply it to given data, and (c) explain a limitation. Practise writing all three answers in under five minutes; the third part is what separates a full-mark answer from an average one.

Applications of Nivolumab/relatlimab

In research: Nivolumab/relatlimab appears in science research whenever the underlying quantities have to be modelled precisely. Papers usually cite it as a starting assumption and then explore where it breaks down.
In technology and industry: Engineering practice reuses Nivolumab/relatlimab in design rules, simulations and safety margins. Knowing the idea lets you read a specification sheet and understand why the numbers look the way they do.
In the classroom: Nivolumab/relatlimab is common in secondary-school and first-year university syllabi. It links to neighbouring topics Antineoplastic drugs, Combination drugs, Drugs developed by Bristol Myers Squibb, so understanding it makes those chapters shorter.
In everyday life: Look for Nivolumab/relatlimab outside the textbook — in sport, cooking, traffic, electronics or the sky above you. An example you found yourself is remembered far longer than one you were given.

Ask Teacher Smith questions about this articleOpens your AI tutor with a question about “Nivolumab/relatlimab” →

Affiliate

Preply — study more efficiently by working with a personal tutor. 50% off.

How to study Nivolumab/relatlimab in 20 minutes

Read the reference excerpt below once, without taking notes.
Close the page and write down what Nivolumab/relatlimab means in your own words.
Compare your version with the excerpt and mark what you missed.
Work through the three examples above with pen and paper.
Explain Nivolumab/relatlimab out loud to somebody else — or to Teacher Smith in the lgStudy chat.

Frequently asked questions

What is Nivolumab/relatlimab in simple terms?

Why does Nivolumab/relatlimab matter?

Because it connects several science ideas at once: it gives you a definition you can apply, a quantity you can calculate, and a way to check whether a result is plausible.

How should I study Nivolumab/relatlimab?

Read the excerpt, restate it from memory, then work through the examples and applications listed on this page. The five-step study plan above takes about twenty minutes.

What does this page cover?

It gives you a compact reference excerpt plus original lgStudy explanations, examples, applications and study material on Nivolumab/relatlimab.